Levi & Korsinsky Investigates Possible Securities Fraud Violations by Biohaven Ltd. (BHVN)Accesswire • 06/09/25
Fraud Investigation: Levi & Korsinsky Investigates Biohaven Ltd. (BHVN) on Behalf of ShareholdersAccesswire • 06/07/25
Levi & Korsinsky Investigating Whether Biohaven Ltd. (BHVN) Misled Investors - Securities Law Violations PossibleAccesswire • 06/06/25
Ongoing Biohaven Ltd. (BHVN) Investigation: Protect Your Rights - Contact Levi & KorsinskyAccesswire • 06/05/25
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Biohaven Ltd. (BHVN)Accesswire • 06/04/25
Shareholders Alert: Investigation Into Biohaven Ltd. (BHVN) - Contact Levi & Korsinsky to Protect Your RightsAccesswire • 06/03/25
Ongoing Investigation: Biohaven Ltd. (BHVN) May Have Misled Shareholders - Levi & Korsinsky InvestigatesAccesswire • 06/02/25
Protect Your Investment: Contact Levi & Korsinsky About the Biohaven Ltd. (BHVN) InvestigationAccesswire • 06/01/25
BHVN Investor Notice: Levi & Korsinsky Investigates Biohaven Ltd. for Securities Law ViolationsAccesswire • 05/30/25
Investors in Biohaven Ltd. (BHVN) Warned of Potential Securities Fraud - Contact Levi & Korsinsky TodayAccesswire • 05/29/25
Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 InhibitorPRNewsWire • 05/29/25
Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN)PRNewsWire • 05/28/25
Lost Money on Biohaven Ltd. (BHVN)? Contact Levi & Korsinsky About InvestigationAccesswire • 05/28/25
Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of TumorsPRNewsWire • 05/28/25
Biohaven Plunges On A Surprise FDA Twist For Its Rare-Disease DrugInvestors Business Daily • 05/15/25
FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar AtaxiaPRNewsWire • 05/14/25
Biohaven Reports First Quarter 2025 Financial Results and Recent Business DevelopmentsPRNewsWire • 05/12/25
Biohaven Is Now A Compelling Contrarian Play Before Troriluzole's FDA VerdictSeeking Alpha • 05/05/25
BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law FirmPRNewsWire • 04/15/25
Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual MeetingPRNewsWire • 04/05/25